Strategies for Achieving Better Cognitive Health in Individuals with Schizophrenia Spectrum: A Focus on the Canadian Landscape: Stratégies pour atteindre une meilleure santé cognitive chez les personnes souffrant du spectre de la schizophrénie : un regard sur le paysage canadien.

Background: Schizophrenia spectrum disorders (SSDs) are a group of psychiatric disorders characterized by positive and negative symptoms as well as cognitive impairment that can significantly affect daily functioning.

Method: We reviewed evidence-based strategies for improving cognitive function in patients with SSDs, focusing on the Canadian landscape.

Results: Although antipsychotic medications can address the positive symptoms of SSDs, cognitive symptoms often persist, causing functional impairment and reduced quality of life.

Brain Imaging in Adolescents and Young Adults With First-Episode Psychosis: A Retrospective Cohort Study.

Objective: Despite the lack of clear guidelines, neuroimaging (computed tomography [CT] or magnetic resonance imaging [MRI]) is frequently performed in subjects presenting with first-episode psychosis (FEP). The objective of this study was to determine if the use of neuroimaging adds diagnostic yield in adolescents and young adults presenting with FEP.

Methods: The sample consisted of 443 subjects aged 15-24 with FEP (DSM-IV-TR and DSM-5) and no focal neurologic findings.

Canadian Guidelines for the Pharmacological Treatment of Schizophrenia Spectrum and Other Psychotic Disorders in Children and Youth.

Objective: Schizophrenia spectrum and other psychotic disorders often have their onset in adolescence. The sequelae of these illnesses can negatively alter the trajectory of emotional, cognitive, and social development in children and youth if left untreated. Early and appropriate interventions can improve outcomes.

Canadian Treatment Guidelines for Individuals at Clinical High Risk of Psychosis.

Objective: Young people who are at clinical high risk (CHR) of developing psychosis are often help seeking and have significant distress and dysfunction. There are limited guidelines for the assessment and treatment for this population. The aim of this guideline was to develop treatment recommendations for this at-risk group.

Guidelines for the Pharmacotherapy of Schizophrenia in Adults.

Objective: The present guidelines address the pharmacotherapy of schizophrenia in adults across different stages, phases, and symptom domains.

Method: Guidelines were developed using the ADAPTE process, which takes advantage of existing guidelines. Six guidelines were identified for adaptation, with recommendations extracted from each.